金泰豐國際控股(08479.HK)上半年扭虧為盈至2799.9萬元
格隆匯8月6日丨金泰豐國際控股(08479.HK)公佈,截至2021年6月30日止6個月,公司收益為人民幣10.82億元,同比增長123.78%;公司擁有人應占期內溢利為人民幣2799.9萬元,去年同期虧損為人民幣430.7萬元,每股盈利為人民幣3.0分。
與2020年同期因COVID-19疫情下的嚴峻情形相比,集團截至2021年6月30日止六個月的收益大幅上升約人民幣5.99億元或123.8%,銷售量亦上升約64,000噸或33.3%。此外,伴隨需求增加,集團亦能從客户取得較好的條款,使毛利率由截至2020年6月30日止六個月的約4.8%上升至2021年同期的約5.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.